GamaMab's Pockets Replenished: Funds For Gynecological Cancer Trials
This article was originally published in Scrip
French biotech GamaMabs Pharma has raised €15m in a series B financing round, led by new investor BioDiscovery 4, with hopes to use the money to fund Phase I and Phase II clinical trials of GamaMabs' lead product GM102 (formerly known as 3C23K) for gynecological cancers.
You may also be interested in...
How to make the most of the wealth of raw data in pharmaceutical R&D is an increasing challenge for the industry. The digital revolution is already having an impact in areas like clinical trials, and pharma is also starting to embrace new technologies in drug discovery.
Technology advancement has brought a wave of change in healthcare, with an increasing number of key pharma players now recognizing the potential of digital – particularly in clinical trials.
This week's roundup includes high-level appointments by Five Prime Therapeutics, Depomed and Gilead Sciences and board appointments by Verseon, Arix Bioscience, and Corbus Pharmaceuticals.